EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
+10.11%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$2.84B
AUM Growth
+$2.84B
(+6.3%)
Cap. Flow
+$31.6M
Cap. Flow
% of AUM
1.11%
Top 10 Holdings %
Top 10 Hldgs %
72.46%
Holding
82
New
9
Increased
14
Reduced
8
Closed
12
Top Buys
| 1 |
Galapagos
GLPG
|
$82M |
| 2 |
Arcus Biosciences
RCUS
|
$62.3M |
| 3 |
Protagonist Therapeutics
PTGX
|
$25.6M |
| 4 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$25.2M |
| 5 |
GRTS
Gritstone bio, Inc. Common Stock
GRTS
|
$23.1M |
Top Sells
| 1 |
Relay Therapeutics
RLAY
|
$97.8M |
| 2 |
TBIO
Translate Bio, Inc. Common Stock
TBIO
|
$28.9M |
| 3 |
Nurix Therapeutics
NRIX
|
$25.2M |
| 4 |
Kymera Therapeutics
KYMR
|
$25.2M |
| 5 |
Arvinas
ARVN
|
$24.8M |
Sector Composition
| 1 | Healthcare | 97.98% |
| 2 | Financials | 0.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Prothena Corp
PRTA
$441M
| $804M | 27.96% | 11,284,280 | – | – |
|
|
MORF
2
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $224M | 7.79% | 3,951,566 | – | – |
|
3
AnaptysBio
ANAB
$569M
| $204M | 7.1% | 7,521,024 | – | – |
|
|
4
Arcus Biosciences
RCUS
$1.13B
| $179M | 6.21% | 5,122,359 +1,787,112 | +54% | +$62.3M |
|
5
Xencor
XNCR
$580M
| $160M | 5.57% | 4,906,106 | – | – |
|
6
Nuvation Bio
NUVB
$1.02B
| $136M | 4.74% | 13,711,517 | – | – |
|
7
Alector
ALEC
$238M
| $114M | 3.97% | 4,994,970 +752,336 | +18% | +$17.2M |
|
|
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $82.1M | 2.86% | 464,298 | – | – |
|
|
9
Galapagos
GLPG
$2.07B
| $82M | 2.85% | +1,558,749 | New | +$82M |
|
10
Shattuck Labs
STTK
$47M
| $75.6M | 2.63% | 3,709,072 +390,662 | +12% | +$7.96M |
|
11
Oric Pharmaceuticals
ORIC
$994M
| $72.5M | 2.52% | 3,468,944 +376,726 | +12% | +$7.88M |
|
12
Kura Oncology
KURA
$686M
| $69.8M | 2.43% | 3,724,437 | – | – |
|
13
Avidity Biosciences
RNA
$5.99B
| $68M | 2.36% | 2,759,505 +655,555 | +31% | +$16.1M |
|
|
GRTS
14
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $60.1M | 2.09% | 5,560,748 +2,139,461 | +63% | +$23.1M |
|
|
15
Relay Therapeutics
RLAY
$619M
| $43.7M | 1.52% | 1,385,276 -3,102,500 | -69% | -$97.8M |
|
16
iTeos Therapeutics
ITOS
| $35.2M | 1.22% | 1,303,157 +267,293 | +26% | +$7.22M |
|
|
17
Nurix Therapeutics
NRIX
$714M
| $33.8M | 1.17% | 1,126,640 -841,310 | -43% | -$25.2M |
|
18
Janux Therapeutics
JANX
$1.37B
| $30.5M | 1.06% | 1,411,975 | – | – |
|
19
Design Therapeutics
DSGN
$315M
| $27.4M | 0.95% | 1,863,098 +603,079 | +48% | +$8.86M |
|
|
20
Protagonist Therapeutics
PTGX
$3.67B
| $25.6M | 0.89% | +1,443,800 | New | +$25.6M |
|
|
DRNA
21
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $25.2M | 0.88% | +1,249,812 | New | +$25.2M |
|
|
AKUS
22
DELISTED
Akouos, Inc. Common Stock
AKUS
| $22.9M | 0.8% | 1,975,984 | – | – |
|
23
Solid Biosciences
SLDB
$427M
| $22M | 0.77% | 9,202,702 | – | – |
|
24
Edgewise Therapeutics
EWTX
$1.51B
| $21.2M | 0.74% | 1,279,175 +55,000 | +4% | +$913K |
|
25
Ovid Therapeutics
OVID
$91M
| $20.4M | 0.71% | 6,082,200 | – | – |
|